Advertisement

Aluminum in Subjects Receiving Parenteral Nutrition

  • Denise Bohrer
Living reference work entry

Abstract

Al is ubiquitous, facilitating potential exposure to this element. Nevertheless, its poor absorption via the gastrointestinal tract protects the vast majority of the population from the risk of Al loading and toxicity. However, when the protective gastrointestinal mechanism is bypassed, as occurs in parenteral nutritional therapy, Al is prone to accumulate in the body. Due to this accumulation, Al is implicated in metabolic bone disease associated with parenteral nutrition in both pediatric and adult patients. Neonates are at an increased risk of aluminum toxicity because of anatomic, physiologic, and nutrition-related factors not present in other populations. Regulatory agencies recommended restricting parenteral aluminum administration to less than 5 μg/kg/day, and the US Food and Drug Administration requires that additives used to compound parenteral nutrition (PN) have the maximum aluminum content at the date of expiration listed on the product label and that large-volume parenterals contain no more than 25 μg/L aluminum. Despite legislative efforts, some factors make it difficult to comply with this rule, and therefore, with the current products used to compound formulations for nutritional therapy, the limits are rarely achieved.

Keywords

Parenteral Nutrition Total Parenteral Nutrition Calcium Gluconate Mental Development Index Parenteral Nutrition Solution 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

List of Abbreviations

EDTA

Ethylenediaminetetraacetic acid

FAO

Food and Agriculture Organization

FDA

Food and Drug Administration

IV

Intravenous

MDI

Mental Development Index

MHRA

Medicine and Healthcare Products Regulatory Agency

NICU

Neonatal intensive care unit

NOAEL

No-observed-adverse-effect level

PN

Parenteral nutrition

PTH

Parathyroid hormone

PTWI

Provisional tolerable weekly intake

TPN

Total parenteral nutrition

WHO

World Health Organization

References

  1. Advenier E, Landry C, Colomb V, et al. Aluminum contamination of parenteral nutrition and aluminum loading in children on long-term parenteral nutrition. J Pediatr Gastroenterol Nutr. 2003;36:448–53.PubMedCrossRefGoogle Scholar
  2. Alfrey AC, LeGendre GR, Kaehny WD. The dialysis encephalopathy syndrome. Possible aluminum intoxication. N Engl J Med. 1976;294(4):184–8.PubMedCrossRefGoogle Scholar
  3. Alfrey AC. Dialysis encephalopathy syndrome. Annu Rev Med. 1978;29:93–8.PubMedCrossRefGoogle Scholar
  4. Alfrey AC. Dialysis encephalopathy. Kidney Int Suppl. 1986;18:S53–7.PubMedGoogle Scholar
  5. Berner YN, Shuler TR, Nielsen FH, et al. Selected ultratrace elements in total parenteral nutrition solutions. Am J Clin Nutr. 1989;50(5):1079–83.PubMedGoogle Scholar
  6. Bishop NJ, Morley R, Day JP, Lucas A. Aluminum neurotoxicity in preterm infants receiving intravenous-feeding solutions. N Engl J Med. 1997;336(22):1557–61.PubMedCrossRefGoogle Scholar
  7. Bohrer D, Dessuy MB, Kaizer R, et al. Tissue digestion for aluminum determination in experimental animal studies. Anal Biochem. 2008;377(2):120–7.PubMedCrossRefGoogle Scholar
  8. Bohrer D, do Nascimento PC, Binotto R, et al. Contribution of the raw material to the aluminum contamination in parenterals. JPEN J Parenter Enteral Nutr. 2002;26(6):382–8.PubMedCrossRefGoogle Scholar
  9. Bohrer D, do Nascimento PC, Binotto R, et al. Influence of the glass packing on the contamination of pharmaceutical products by aluminium. Part III: interaction container-chemicals during the heating for sterilization. J Trace Elem Med Biol. 2003;17(2):107–15.PubMedCrossRefGoogle Scholar
  10. Bohrer D, Oliveira SM, Garcia SC, et al. Aluminum loading in preterm neonates revisited. J Pediatr Gastroenterol Nutr. 2010;51(2):237–41.PubMedCrossRefGoogle Scholar
  11. Bougle D, Bureau F, Voirin J, et al. A cross-sectional study of plasma and urinary aluminum levels in term and preterm infants. JPEN J Parenter Enteral Nutr. 1992;16(2):157–9.PubMedCrossRefGoogle Scholar
  12. Cann CE, Prussin SG, Gordan GS. Aluminum uptake by the parathyroid glands. J Clin Endocrinol Metab. 1979;49(4):543–5.PubMedCrossRefGoogle Scholar
  13. Committee on Nutrition. American Academy of Pediatrics. Aluminum toxicity in infants and children. Pediatrics. 1986;78:1150–4.Google Scholar
  14. Committee on Nutrition. American Academy of Pediatrics. Aluminum toxicity in infants and children. Pediatrics. 1996;97:413–16.Google Scholar
  15. Committee on Nutrition. American Academy of Pediatrics. Aluminum toxicity in infants and children. Pediatrics. 2004;114:26.Google Scholar
  16. de Oliveira SR, Bohrer D, Garcia SC, et al. Aluminum content in intravenous solutions for administration to neonates: role of product preparation and administration methods. JPEN J Parenter Enteral Nutr. 2010;34(3):322–8.PubMedCrossRefGoogle Scholar
  17. Department of Health and Human Services, Food and Drug Administration. Parenteral drug products containing aluminum as an ingredient or a contaminant: notice of intent and request for information. Fed Regist. 1990;55:20799–802.Google Scholar
  18. Department of Health and Human Services, Food and Drug Administration. Amendment of regulations on parenteral nutrition; delay of effective date. Fed Regist. 2003;68:32979–81.Google Scholar
  19. European Food Safety Authority. Safety of aluminium from dietary intake – scientific opinion of the panel on food additives, flavourings, processing aids and food contact materials (AFC). The EFSA Journal. 2008;754:1–88.Google Scholar
  20. Fernández-Martín JL, Menéndez-Fraga P, Canteros MA, et al. Binding of aluminium to plasma proteins: comparative effect of desferrioxamine and deferiprone (L1). Clin Chim Acta. 1994;230(2):137–45.PubMedCrossRefGoogle Scholar
  21. Ferrone M, Geraci M. A review of the relationship between parenteral nutrition and metabolic bone disease. Nutr Clin Pract. 2007;22(3):329–39.PubMedCrossRefGoogle Scholar
  22. Fewtrell MS, Edmonds CJ, Isaacs E, et al. Aluminium exposure from parenteral nutrition in preterm infants and later health outcomes during childhood and adolescence. Proc Nutr Soc. 2011;70(3):299–304.PubMedCrossRefGoogle Scholar
  23. Frank EL, Hughes MP, Bankson DD, et al. Effects of anticoagulants and contemporary blood collection containers on aluminum, copper, and zinc results. Clin Chem. 2001;47(6):1109–12.PubMedGoogle Scholar
  24. Garcia SC, Gioda A, Bohrer D. The problem of contamination in aluminum trace analysis. Quim Nova. 1997;20(4):1–5.CrossRefGoogle Scholar
  25. Harigaya K, Kuwahara Y, Nishi H. Determination of aluminum in large volume parenteral drug products used in total parenteral nutrition therapy by ICP-MS with a dynamic reaction cell. Chem Pharm Bull (Tokyo). 2008;56(4):475–9.CrossRefGoogle Scholar
  26. Hellström HO, Mjöberg B, Mallmin H, et al. The aluminum content of bone increases with age, but is not higher in hip fracture cases with and without dementia compared to controls. Osteoporos Int. 2005;16(12):1982–8.PubMedCrossRefGoogle Scholar
  27. Heyman MB, Klein GL, Wong A, et al. Aluminum does not accumulate in teenage and adult patients receiving total parenteral nutrition containing amino acids. JPEN J Parenter Enteral Nutr. 1986;10(1):86–7.PubMedCrossRefGoogle Scholar
  28. Joint FAO/WHO Expert Committee on Food Additives. Seventy-fourth meeting. Summary and conclusions, Rome. 2011. ftp://ftp.fao.org/ag/agn/%E2%80%A6/JECFA_74_Summary_Report_4July2011.pdf. Accessed 15 May 2013.
  29. Klein GL, Ament ME, Coburn JW. Metabolic bone disease in total parenteral nutrition. Lancet. 1981a;1(8224):835.PubMedCrossRefGoogle Scholar
  30. Klein GL, Coburn JW. Total parenteral-nutrition and its effects on bone metabolism. Crit Rev Clin Lab Sci. 1994;31(2):135–67.PubMedCrossRefGoogle Scholar
  31. Klein GL, Horst RL, Norman AW, et al. Reduced serum levels of 1-alpha, 25-dihydroxyvitamin D during long-term parenteral nutrition. Ann Intern Med. 1981b;94(5):638–43.PubMedCrossRefGoogle Scholar
  32. Klein GL, Leichtner AM, Heyman MB. The Patient Care Committee of the North American Society for Pediatric Gastroenterology and Nutrition: aluminum in large and small volume parenterals used in total parenteral nutrition: response to the Food and Drug Administration notice of proposed rule by the North American Society for Pediatric Gastroenterology and Nutrition. J Pediatr Gastroenterol Nutr. 1998;27:457–60.PubMedCrossRefGoogle Scholar
  33. Klein GL. Aluminum contamination of parenteral nutrition solutions and its impact on the pediatric patient. Nutr Clin Pract. 2003;18(4):302–7.PubMedCrossRefGoogle Scholar
  34. Koo WW, Kaplan LA, Bendon R, et al. Response to aluminum in parenteral nutrition during infancy. J Pediatr. 1986;109(5):877–83.PubMedCrossRefGoogle Scholar
  35. Koo WW, Kaplan LA, Krug-Wispe SK, et al. Response of preterm infants to aluminum in parenteral nutrition. JPEN J Parenter Enteral Nutr. 1989;13(5):516–19.PubMedCrossRefGoogle Scholar
  36. Medicines and Healthcare products Regulatory Agency- MHRA (UK). Calcium gluconate 10 % in 10 mL glass containers: risk of aluminium exposure. Public assessment report, Sept 2010.Google Scholar
  37. Moreno A, Domínguez C, Ballabriga A. Aluminum in the neonate related to parenteral nutrition. Acta Paediatr. 1994;83(1):25–9.PubMedCrossRefGoogle Scholar
  38. Morrissey J, Rothstein M, Mayor G, et al. Suppression of parathyroid hormone secretion by aluminum. Kidney Int. 1983;23(5):699–704.PubMedCrossRefGoogle Scholar
  39. Ogasawara Y, Sakamoto T, Ishii K, et al. Effects of the administration routes and chemical forms of aluminum on aluminum accumulation in rat brain. Biol Trace Elem Res. 2002;86(3):269–78.PubMedCrossRefGoogle Scholar
  40. Ott SM, Maloney NA, Coburn JW, et al. The prevalence of bone aluminum deposition in renal osteodystrophy and its relation to the response to calcitriol therapy. N Engl J Med. 1982;307(12):709–13.PubMedCrossRefGoogle Scholar
  41. Ott SM, Maloney NA, Klein GL, et al. Aluminum is associated with low bone formation in patients receiving chronic parenteral nutrition. Ann Intern Med. 1983;98:910–14.PubMedCrossRefGoogle Scholar
  42. Poole RL, Pieroni KP, Gaskari S, et al. Aluminum in pediatric parenteral nutrition products: measured versus labeled content. J Pediatr Pharmacol Ther. 2011;16(2):92–7.PubMedCentralPubMedGoogle Scholar
  43. Poole RL, Hintz SR, Mackenzie NI, et al. Aluminum exposure from pediatric parenteral nutrition: meeting the new FDA regulation. JPEN J Parenter Enteral Nutr. 2008;32:242–6.PubMedCrossRefGoogle Scholar
  44. Sánchez-Iglesias S, Soto-Otero R, Iglesias-González J, et al. Analysis of brain regional distribution of aluminium in rats via oral and intraperitoneal administration. J Trace Elem Med Biol. 2007;21:31–4.PubMedCrossRefGoogle Scholar
  45. Sedman AB, Klein GL, Merritt RJ, et al. Evidence of aluminum loading in infants receiving intravenous therapy. N Engl J Med. 1985;312(21):1337–43.PubMedCrossRefGoogle Scholar
  46. Smith BS, Kothari H, Hayes BD, et al. Effect of additive selection on calculated aluminum content of parenteral nutrient solutions. Am J Health Syst Pharm. 2007;64(7):730–9.PubMedCrossRefGoogle Scholar
  47. The American Society for Clinical Nutrition/American Society for Parenteral and Enteral Nutrition Working Group on Standards for Aluminum Content of Parenteral Nutrition Solutions. Parenteral drug products containing aluminum as an ingredient or a contaminant: Response to Food and Drug Administration notice of intent and request for information. Am J Clin Nutr. 1991;53:399–402.Google Scholar
  48. Tomljenovic L. Aluminum and Alzheimer’s disease: after a century of controversy, is there a plausible link? J Alzheimers Dis. 2011;23(4):567–98.PubMedGoogle Scholar
  49. US FDA Department of Health and Human Services, Food and Drug Administration. Aluminum in large and small volume parenterals used in total parenteral nutrition: title 21, vol 4, Revised as of 1 April 2013.Google Scholar
  50. Vargas JH, Klein GL, Ament ME, et al. Metabolic bone disease of total parenteral nutrition course after changing from casein to amino acids in parenteral solutions with reduced aluminum content. Am J Clin Nutr. 1988;48(4):1070–8.PubMedGoogle Scholar
  51. WHO. Food additives series 65: safety evaluation of certain food additives and contaminants. Geneva: World Health Organization; 2011.Google Scholar
  52. Wilhelm M, Hoelzer J, Luebbers K, et al. Aluminum balance in intensive care patients. J Trace Elem Med Biol. 2001;14(4):223–7.PubMedCrossRefGoogle Scholar
  53. Zhou Y, Harris WR, Yokel RA. The influence of citrate, maltolate and fluoride on the gastrointestinal absorption of aluminum at a drinking water-relevant concentration: A 26Al and 14C study. J Inorg Biochem. 2008;102(4):789–808.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  1. 1.Department of ChemistryFederal University of Santa MariaSanta MariaBrazil

Personalised recommendations